Market Overview

This Firm Is Still Selling Texas Instruments On Lofty Valuation, Apple Exposure

This Firm Is Still Selling Texas Instruments On Lofty Valuation, Apple Exposure

Goldman Sachs is still selling Texas Instruments Incorporated (NASDAQ: TXN) and sees 16.5 percent downside to its price target of $51 due to elevated multiples and limited headroom for additional margin optimization.

The brokerage also expects the company's exposure to Apple Inc. (NASDAQ: AAPL) provide further earnings and multiple risk over the next twelve months.

On the margin front, Texas Instruments increased its gross margins 830 bps between 2012 and 2015 by cutting 540 bps from opex (primarily R&D) as a percent of revenue over the same period. However, Goldman sees little room for these decreases to continue.

"We believe further R&D cuts would jeopardize what we already view as a tepid top-line growth environment and accordingly do not model further opex reduction," analyst Toshiya Hari wrote in a note.

Meanwhile, TXN shares still trades at an elevated level despite concerns around future growth headwinds. Hari said the stock's current NTM P/E is nearly 10 percent above the company's 5-year average and represents a 2.2x turn premium to GS' analog coverage and a 5.7x turn premium to the SOX.

Hari expects the stock to re-rate negatively once investors fully appreciate the company's limited headroom for further cost reductions.

At the time of writing, shares of Texas Instruments fell 0.60 percent to $60.71.

Posted-In: Goldman Sachs Toshiya HariAnalyst Color News Price Target Reiteration Analyst Ratings Best of Benzinga


Related Articles (AAPL + TXN)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Sarpeta Shares Slammed On Possible Reason For Delay In FDA Final Decision On Eteplirsen

GlaxoSmithKline, Innoviva Offer Regulatory Update on US Filing Plans for Closed Triple Combo Therapy FF/UMEc/VI for Patients with COPD